Race Oncology Ltd - ESG Rating & Company Profile powered by AI
Check the end of the page for potential risks for Race Oncology Ltd based on sector, location and size. The SDG assessment for Race Oncology Ltd represents the company's reporting of the UN Sustainable Development Goals. The analysis of Race Oncology Ltd incorporates intelligence from across the web and also from public filings by Race Oncology Ltd.
Race Oncology Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 6.1; made up of an environmental score of 4.0, social score of 8.0 and governance score of 6.4.
6.1
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 450 | Valneva USA Inc | 6.2 | High |
| 450 | Sino Biopharmaceutical Ltd | 6.2 | High |
| 483 | Race Oncology Ltd | 6.1 | High |
| 483 | Bora Pharmaceuticals Co Ltd | 6.1 | High |
| 483 | Affimed NV | 6.1 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Race Oncology Ltd have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Race Oncology Ltd disclose current and historical energy intensity?
Sign up for free to unlockDoes Race Oncology Ltd report the average age of the workforce?
Sign up for free to unlockDoes Race Oncology Ltd reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Race Oncology Ltd disclose its ethnicity pay gap?
Sign up for free to unlockDoes Race Oncology Ltd disclose cybersecurity risks?
Sign up for free to unlockDoes Race Oncology Ltd offer flexible work?
Sign up for free to unlockDoes Race Oncology Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Race Oncology Ltd disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Race Oncology Ltd conduct supply chain audits?
Sign up for free to unlockDoes Race Oncology Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Race Oncology Ltd conduct 360 degree staff reviews?
Sign up for free to unlockDoes Race Oncology Ltd disclose the individual responsible for D&I?
Sign up for free to unlockDoes Race Oncology Ltd disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Race Oncology Ltd disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Race Oncology Ltd disclose water use targets?
Sign up for free to unlockDoes Race Oncology Ltd have careers partnerships with academic institutions?
Sign up for free to unlockDid Race Oncology Ltd have a product recall in the last two years?
Sign up for free to unlockDoes Race Oncology Ltd disclose incidents of discrimination?
Sign up for free to unlockDoes Race Oncology Ltd allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Race Oncology Ltd issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Race Oncology Ltd disclose parental leave metrics?
Sign up for free to unlockDoes Race Oncology Ltd disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Race Oncology Ltd disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Race Oncology Ltd disclose the pay ratio of women to men?
Sign up for free to unlockDoes Race Oncology Ltd support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Race Oncology Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Race Oncology Ltd reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Race Oncology Ltd involved in embryonic stem cell research?
Sign up for free to unlockDoes Race Oncology Ltd disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Race Oncology Ltd disclose its waste policy?
Sign up for free to unlockDoes Race Oncology Ltd report according to TCFD requirements?
Sign up for free to unlockDoes Race Oncology Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Race Oncology Ltd disclose energy use targets?
Sign up for free to unlockDoes Race Oncology Ltd disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Race Oncology Ltd have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Race Oncology Ltd
These potential risks are based on the size, segment and geographies of the company.
Race Oncology Limited operates as a precision oncology company in Australia. The company is developing Zantrene, a potent small molecule inhibitor of the fatso/fat mass and obesity associated protein to treat for melanoma and clear cell renal cell carcinoma, as well as acute myeloid leukaemia, breast, and ovarian cancers, which is in Phase II/III clinical trial. It has a preclinical research program with the University of Newcastle for investigating Zantrene; and strategic collaboration with the University of Wollongong to evaluate Zantrene formulations. The company was formerly known as Coronado Resources Limited and changed its name to Race Oncology Limited in July 2016. Race Oncology Limited was incorporated in 2011 and is based in Sydney, Australia.